Alpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate.Povetacicept has shown ...
Source LinkAlpine Immune Sciences has discarded two drug candidates since joining the Nasdaq in 2027, but its stock price has risen >200% in six months owing to its latest lead candidate.Povetacicept has shown ...
Source Link
Comments